申请人:BAYER PHARMA AKTIENGESELLSCHAFT
公开号:US20160193206A1
公开(公告)日:2016-07-07
The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydropyridopyrazinones of the general formula (I)
in which A, X, R
1
, R
2
, R
3
, R
4
, R
4
, R
6
, R
7
and n have the meanings given in the description, to intermediates for preparation of the compounds according to the invention, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders.
This invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.
本发明涉及BET蛋白抑制剂,特别是BRD4抑制剂,通式(I)所示的二氢吡啶吡唑酮,其中A、X、R1、R2、R3、R4、R4、R6、R7和n在说明书中给出其含义,以及制备本发明化合物的中间体,包含本发明化合物的制药组合物,以及在高增殖性疾病,特别是恶性肿瘤疾病的预防和治疗中的预防和治疗用途。本发明还涉及在病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化性疾病和男性生育控制中使用BET蛋白抑制剂。